Latest news with #RDNT
Yahoo
a day ago
- Business
- Yahoo
RadNet (RDNT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
For the quarter ended June 2025, RadNet (RDNT) reported revenue of $498.23 million, up 8.4% over the same period last year. EPS came in at $0.31, compared to $0.16 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $488.57 million, representing a surprise of +1.98%. The company delivered an EPS surprise of +82.35%, with the consensus EPS estimate being $0.17. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance. As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately. Here is how RadNet performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenue- Digital Health: $20.7 million compared to the $19.92 million average estimate based on two analysts. The reported number represents a change of +31% year over year. Revenue- Revenue under capitation arrangements: $30.17 million versus the two-analyst average estimate of $33.19 million. Revenue- Service fee: $468.06 million versus $459.02 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +10.7% change. View all Key Company Metrics for RadNet here>>> Shares of RadNet have returned -3.8% over the past month versus the Zacks S&P 500 composite's +2.7% change. The stock currently has a Zacks Rank #5 (Strong Sell), indicating that it could underperform the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report RadNet, Inc. (RDNT) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
3 days ago
- Business
- Yahoo
Is Now An Opportune Moment To Examine RadNet, Inc. (NASDAQ:RDNT)?
RadNet, Inc. (NASDAQ:RDNT), might not be a large cap stock, but it saw significant share price movement during recent months on the NASDAQGM, rising to highs of US$61.14 and falling to the lows of US$51.03. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether RadNet's current trading price of US$54.69 reflective of the actual value of the mid-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let's take a look at RadNet's outlook and value based on the most recent financial data to see if there are any catalysts for a price change. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. What Is RadNet Worth? The stock seems fairly valued at the moment according to our valuation model. It's trading around 16% below our intrinsic value, which means if you buy RadNet today, you'd be paying a fair price for it. And if you believe that the stock is really worth $65.29, then there isn't much room for the share price grow beyond what it's currently trading. So, is there another chance to buy low in the future? Given that RadNet's share is fairly volatile (i.e. its price movements are magnified relative to the rest of the market) this could mean the price can sink lower, giving us an opportunity to buy later on. This is based on its high beta, which is a good indicator for share price volatility. View our latest analysis for RadNet What does the future of RadNet look like? Future outlook is an important aspect when you're looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Although value investors would argue that it's the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. Though in the case of RadNet, it is expected to deliver a relatively unexciting top-line growth of 7.0% over the next year, which doesn't help build up its investment thesis. Growth doesn't appear to be a main reason for a buy decision for the company, at least in the near term. What This Means For You Are you a shareholder? RDNT's future growth appears to have been factored into the current share price, with shares trading around its fair value. However, there are also other important factors which we haven't considered today, such as the track record of its management team. Have these factors changed since the last time you looked at the stock? Will you have enough confidence to invest in the company should the price drop below its fair value? Are you a potential investor? If you've been keeping tabs on RDNT, now may not be the most optimal time to buy, given it is trading around its fair value. However, the positive outlook means it's worth diving deeper into other factors such as the strength of its balance sheet, in order to take advantage of the next price drop. With this in mind, we wouldn't consider investing in a stock unless we had a thorough understanding of the risks. At Simply Wall St, we found 1 warning sign for RadNet and we think they deserve your attention. If you are no longer interested in RadNet, you can use our free platform to see our list of over 50 other stocks with a high growth potential. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
3 days ago
- Business
- Yahoo
3 Reasons to Avoid RDNT and 1 Stock to Buy Instead
Over the past six months, RadNet's shares (currently trading at $56.54) have posted a disappointing 16.8% loss, well below the S&P 500's 5% gain. This might have investors contemplating their next move. Is there a buying opportunity in RadNet, or does it present a risk to your portfolio? Dive into our full research report to see our analyst team's opinion, it's free. Why Is RadNet Not Exciting? Despite the more favorable entry price, we're cautious about RadNet. Here are three reasons why you should be careful with RDNT and a stock we'd rather own. 1. Fewer Distribution Channels Limit its Ceiling Larger companies benefit from economies of scale, where fixed costs like infrastructure, technology, and administration are spread over a higher volume of goods or services, reducing the cost per unit. Scale can also lead to bargaining power with suppliers, greater brand recognition, and more investment firepower. A virtuous cycle can ensue if a scaled company plays its cards right. With just $1.87 billion in revenue over the past 12 months, RadNet is a small company in an industry where scale matters. This makes it difficult to build trust with customers because healthcare is heavily regulated, complex, and resource-intensive. 2. Free Cash Flow Margin Dropping If you've followed StockStory for a while, you know we emphasize free cash flow. Why, you ask? We believe that in the end, cash is king, and you can't use accounting profits to pay the bills. As you can see below, RadNet's margin dropped by 3.9 percentage points over the last five years. Almost any movement in the wrong direction is undesirable because of its already low cash conversion. If the trend continues, it could signal it's becoming a more capital-intensive business. RadNet's free cash flow margin for the trailing 12 months was 1.8%. 3. Previous Growth Initiatives Haven't Impressed Growth gives us insight into a company's long-term potential, but how capital-efficient was that growth? A company's ROIC explains this by showing how much operating profit it makes compared to the money it has raised (debt and equity). RadNet historically did a mediocre job investing in profitable growth initiatives. Its five-year average ROIC was 6.4%, somewhat low compared to the best healthcare companies that consistently pump out 20%+. Final Judgment RadNet isn't a terrible business, but it isn't one of our picks. Following the recent decline, the stock trades at 106.9× forward P/E (or $56.54 per share). At this valuation, there's a lot of good news priced in - we think there are better stocks to buy right now. We'd recommend looking at a dominant Aerospace business that has perfected its M&A strategy. High-Quality Stocks for All Market Conditions Donald Trump's April 2024 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities. The smart money is already positioning for the next leg up. Don't miss out on the recovery - check out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Business
- Yahoo
Wall Street's Insights Into Key Metrics Ahead of RadNet (RDNT) Q2 Earnings
Analysts on Wall Street project that RadNet (RDNT) will announce quarterly earnings of $0.17 per share in its forthcoming report, representing an increase of 6.3% year over year. Revenues are projected to reach $488.57 million, increasing 6.3% from the same quarter last year. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe. Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock. While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding. Bearing this in mind, let's now explore the average estimates of specific RadNet metrics that are commonly monitored and projected by Wall Street analysts. The consensus estimate for 'Revenue- Imaging Center' stands at $467.90 million. The estimate indicates a year-over-year change of +3.9%. The average prediction of analysts places 'Revenue- Service fee' at $459.02 million. The estimate indicates a change of +8.6% from the prior-year quarter. The combined assessment of analysts suggests that 'Revenue- Digital Health' will likely reach $19.92 million. The estimate points to a change of +26% from the year-ago quarter. View all Key Company Metrics for RadNet here>>> Over the past month, shares of RadNet have returned +0.3% versus the Zacks S&P 500 composite's +0.5% change. Currently, RDNT carries a Zacks Rank #5 (Strong Sell), suggesting that it may underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> . Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report RadNet, Inc. (RDNT) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Business
- Yahoo
RadNet, Inc. Announces Date of its Second Quarter 2025 Financial Results Conference Call
LOS ANGELES, July 25, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers and digital health solutions, announced today that it will host a conference call to discuss its second quarter 2025 financial results on Monday, August 11, 2025 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time). Investors are invited to listen to RadNet's conference call by dialing 844-826-3035. International callers can dial 412-317-5195. There will also be simultaneous and archived webcasts available at An archived replay of the call will also be available and can be accessed by dialing 844-512-2921 from the U.S., or 412-317-6671 for international callers, and using the passcode 10201853. About RadNet, Inc. RadNet, Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 401 owned and/or operated outpatient imaging centers. RadNet's markets include Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has a total of over 11,000 employees. For more information, visit Inc. Mark Stolper Executive Vice President and Chief Financial Officer 310-445-2800
